沙格列汀对初诊2型糖尿病合并代谢综合征患者糖脂代谢的影响

Effects of Saxagliptin on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome at Initial Diagnosis

目的探讨沙格列汀对初诊2型糖尿病(T2DM)合并代谢综合征(MS)患者糖脂代谢的影响。方法选取2018年6月至2020年2月商丘市第五人民医院收治的80例初诊T2DM合并MS患者作为研究对象,按照治疗方法分为对照组与观察组,各40例。对照组接受二甲双胍治疗,观察组接受沙格列汀治疗。比较两组治疗前以及治疗3个月后的血糖[空腹血糖(FPG)、餐后2小时血糖(2 h PG)、糖化血红蛋白(HbA1c)]、血脂[血甘油三酯(TG)、高密度脂蛋白(HDL-C)、总胆固醇(TC)、低密度脂蛋白(LDL-C)]水平,比较两组不良反应发生情况。结果治疗前,两组FPG、HbA1c、2 h PG水平比较,差异无统计学意义(P>0.05);治疗3个月后,两组FPG、HbA1c、2 h PG水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组LDL-C、TC、TG、HDL-C水平比较,差异无统计学意义(P>0.05);治疗3个月后,两组LDL-C、TC、TG水平均降低,且观察组低于对照组,两组HDL-C均升高,且观察组高于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论沙格列汀可改善初诊T2DM合并MS患者的糖脂代谢水平,且不会增加不良反应。

Objective To explore the effects of saxagliptin on glucose and lipid metabolism in patients with type 2 diabetes mellitus(T2DM)and metabolic syndrome(MS)at initial diagnosis.Methods The clinical data of 80 patients with T2DM and MS at initial diagnosis in Shangqiu Fifth People’s Hospital from June 2018 to February 2020 were retrospectively analyzed,the patients were divided into two groups by treating method and the control group(n=40)accepted metformin,the study group(n=40)accepted saxagliptin.The levels of blood glucose[fasting plasma glucose(FPG),2-hour postprandial blood glucose(2 h PG),glycosylated hemoglobin(HbA1c)],blood lipid[serum triglyceride(TG),high-density lipoprotein cholesterol(HDL-C),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)]before and after 3 months’treatment were compared between the two groups,and the adverse reactions of the two groups were compared.Results After 3 months’treatment,the levels of FPG,HbA1c and 2 h PG of both groups were decreased,and the levels of FPG,HbA1c and 2 h PG of the study group were lower than those of the control group(P<0.05).After 3 months’treatment,the levels of LDL-C,TC,TG of both groups were decreased,the level of HDL-C was increased(P<0.05).The levels of LDL-C,TC,TG of the study group were lower than those of the control group,and the level of HDL-C of the study group was higher than that of the control group(P<0.05).There was no statistical difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Saxagliptin can improve the glucose and lipid metabolism level of patients with T2DM and MS at initial diagnosis without increasing the occurrence of adverse reactions,which is worthy of promotion.